The humble ink in a tattoo artist’s needle could be the key to improving the detection of cancer, thanks to new research from the University of Southern California Viterbi Department of Biomedical Engineering, USA.
WiSE Gabilan Assistant Professor in the department with a lab at the USC Michelson Center for Convergent Bioscience, Cristina Zavaleta and her team recently developed new imaging contrast agents using common dyes such as tattoo ink and food dyes.
When these dyes are attached to nanoparticles, they can illuminate cancers, allowing medical professionals to better differentiate between cancer cells and normal adjacent cells.
The work has been published in Biomaterials Science.
Early detection is crucial for patients to have the best possible outcomes from cancer; a disease that will affect over 38% of Americans at some point in their lifetime.
However, detection is challenging without good imaging agents; contrast materials which when injected into patients, allow for imaging such as MRI and CT to function with better sensitivity and specificity, enabling medical professionals to diagnose with accuracy, and for surgeons to identify the exact margins of tumours.
“For instance, if the problem is colon cancer, this is detected via endoscopy,” Zavaleta said. “But an endoscope is literally just a flashlight on the end of a stick, so it will only give information about the structure of the colon - you can see a polyp and know you need to take a biopsy.”
“But if we could provide imaging tools to help doctors see whether that particular polyp is cancerous or just benign, maybe they don’t even need to take it,” she said.
Illuminated nanoparticles move through a blood vessel to find cancer.
The colouring dyes were incorporated into nanoparticles to allow for more sensitive imaging contrast when identifying cancerous cells.
To achieve this, the team has discovered a unique source of optical contrasting agents from the household colouring dyes and pigments that we routinely encounter.
These “optical inks” can be attached to cancer-targeting nanoparticles to improve cancer detection and localisation.
The dyes and pigments were discovered from common colouring agents that already have U.S. Food and Drug Administration (FDA) approval, which the team hopes may enable them to be more easily and safely implemented in imaging practice.
For Zavaleta, inspiration struck in an unusual place — an animation class with Pixar artists in Emeryville, California, the home of the famed studio.
Zavaleta, who enjoys art and animation among her hobbies, said she was intrigued by the inks and paints that the artists brought to class.
“I was thinking about how these really high pigment paints, like gouache watercolours, were bright in a way I hadn’t seen before, and I was wondering if they had interesting optical properties,” Zavaleta said.
The idea led her to tattoo artist in nearby San Francisco, Adam Sky, another artisan working with bright dyes.
“I remember I brought a 96-well plate and he squirted tattoo ink into each of the wells,” Zavaleta said. “Then I took the inks to our Raman scanner (used to sensitively detect our tumour-targeting nanoparticles) and discovered these really amazing spectral fingerprints that we could use to barcode our nanoparticles. It was super cool.”
One of the safety challenges of imaging using nanoparticles, is that often these nanoparticles can have a prolonged retention in organs like the liver and the spleen, which are responsible for trying to break down the nanoparticle.
Because of these safety concerns, it’s crucial to consider biodegradable nanomaterials.
Currently, there are a limited amount of optical contrast agents approved for clinical use.
With this in mind, Zavaleta’s team considered common food dyes that could be used to decorate the nanoparticles, such as the dyes found in colourful candies like Skittles and M&Ms.
These brightly coloured food products that humans routinely consume have been deemed by the FDA as safe for human consumption.
“We thought, let’s look at some of the FDA-approved drug, cosmetic and food dyes that exist and see what optical properties are amongst those dyes,” Zavaleta said. “And so that’s where we ended up finding that many of these FDA-approved dyes have interesting optical properties that we could exploit for imaging.”
The team has developed a nanoparticle that will carry these highly pigmented imaging agents as a “payload.”
Zavaleta said the particles are of a specific size that enables them to passively penetrate into tumour areas, but can also be retained due to their size.
Most of the imaging contrast agents used in the clinic today are small molecule dyes.
“With small molecules, you may be able to see them accumulate in tumour areas initially, but you’d have to be quick before they end up leaving the tumour area to be excreted,” Zavaleta said. “Our nanoparticles happen to be small enough to seep through, but at the same time big enough to be retained in the tumour, and that’s what we call the enhanced permeability and retention effect.”
The nanoparticle can also be “decorated” with a larger payload of the dye than previous small molecule imaging agents, which the team has shown under fluorescence imaging leads to brighter signal and significant localisation of the nanoparticles in tumours.
“If you encapsulate a bunch of dyes in a nanoparticle, you’re going to be able to see it better because it is going to be brighter,” Zavaleta said. “It’s like using a packet of dyes rather than just one single dye.”